TrippBio
Early Stage
TrippBio is developing a new, therapeutic application of an FDA-approved drug with a high probability to be proven safe and efficacious in the treatment and prevention of the SARS-CoV-2 virus that causes COVID-19.
Overview
Raised: $185,796
Total Commitments ($USD)
Platform
Netcapital
Start Date
09/15/2020
Close Date
01/29/2021
Min. Goal
$10,000
Max. Goal
$1,070,000
Min. Investment
$100
Security Type
Equity - Common
Series
Pre-Seed
SEC Filing Type
RegCF
/ RegD 506(c)
Price Per Share
$4.00
Pre-Money Valuation
$5,255,840
Rolling Commitments ($USD)
Status
Funded
Reporting Date
01/30/2021
Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise
$1,376
Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Year Founded
2020
Industry
Healthcare & Pharmaceuticals
Tech Sector
HealthTech
Distribution Model
B2B
Margin
Medium
Capital Intensity
High
TrippBio, with a post-money valuation of $7.1 million, is raising funds on NetCapital. The company is developing a new therapeutic application of an FDA-approved drug for the treatment and prevention of the SARS-CoV-2 virus. The company believes that the drug TD213 is capable of preventing the host cell from assembling the virus that causes COVID-19. Billy Meadow and Richard Still founded TrippBio in May 2020. The current round of crowdfunding has a minimum raise of $10,000 and a maximum raise of $1,070,000, and the funds will be used for initial clinical trial, development and manufacturing of TD213, marketing and advertising, professional services, and ramp-up clinical trial. TrippBio is well-positioned to help the world combat COVID-19 and other infectious diseases.
Summary Profit and Loss Statement
| Most Recent Year | Prior Year | |
|---|---|---|
|
Revenue |
$0 |
$0 |
|
COGS |
$0 |
$0 |
|
Tax |
$0 |
$0 |
| ||
| ||
|
Net Income |
$0 |
$0 |
Summary Balance Sheet
| Most Recent Year | Prior Year | |
|---|---|---|
|
Cash |
$0 |
$0 |
|
Accounts Receivable |
$0 |
$0 |
|
Total Assets |
$0 |
$0 |
|
Short-Term Debt |
$0 |
$0 |
|
Long-Term Debt |
$0 |
$0 |
|
Total Liabilities |
$0 |
$0 |
Financials as of: 09/15/2020
Create a free account today to gain access to KingsCrowd analytics.
Upgrade to gain access
Pay Monthly
Annually (Save 17%)
-
$25 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Already a member? Log in here.
Ratings 
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.